Skip to main content

Yu Shyr Archives

Data haul improves immunotherapy response prediction

Jan. 16, 2024—Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

Read more


Clinical trial shows efficacy for atezolizumab combined with carboplatin

Dec. 15, 2023—by Tom Wilemon Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best. Vanderbilt researchers led a clinical trial combining atezolizumab, an...

Read more


How biostatistics saves lives: the Vanderbilt experience

Oct. 17, 2023—Biostatisticians at VUMC have played a pivotal role in the redesign of clinical trials that rigorously and rapidly determine the effectiveness of life-saving treatments for acutely ill patients.

Read more


VUMC’s Pietenpol, Shyr named AACR Fellows

Mar. 22, 2022—Vanderbilt's Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.

Read more


Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

Jan. 14, 2022—A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

Read more


Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Apr. 15, 2021—Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

Read more


Multinational consortium reports COVID-19 impact on cancer patients

May. 28, 2020—People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

Read more


Research team awarded $9 million to study extracellular RNA in colorectal cancer

Apr. 9, 2020—The NCI program project grant is supporting multiple projects that aim to define fundamental biological principles about extracellular RNA signaling and the development and aggressiveness of colorectal cancer, the second leading cause of cancer death in the United States.

Read more


Lewis’ Discovery Lecture

Jan. 18, 2018—Clinical trials expert Roger Lewis, MD, PhD, right, poses with Vanderbilt’s Yu Shyr, MD, following his recent Discovery Lecture. Lewis is chair of Emergency Medicine at Harbor-UCLA Medical Center in Los Angeles.

Read more


Shyr named chair of Department of Biostatistics

Jul. 20, 2017—Yu Shyr, Ph.D., Harold L. Moses Professor of Cancer Research and director of the Vanderbilt Center for Quantitative Sciences, has been named chair of Vanderbilt’s Department of Biostatistics. He will assume the post Sept. 1.

Read more


Nine Vanderbilt faculty members elected AAAS fellows

Nov. 25, 2016—Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year.

Read more


VICC investigators in spotlight at AACR conference

May. 19, 2016—A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more